Mutations in human dysferlin (DYSF) gene cause both limb girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM), also named dysferlinopathy. They are autosomal recessive muscular dystrophies characterized by degeneration and weakness of proximal and/or distal limb girdle muscles caused by partial or complete absence of a sarcolemmal protein dysferlin. The size and large mutational spectrum of DYSF impose a multistep diagnosis strategy before gene analysis. Here we report the first three patients from two unrelated Croatian families in which diagnosis of dysferlinopathy was suggested on the basis of clinical picture, family history and linkage analysis. In order to confirm the presumed diagnosis, we performed a blood-based assay in which dysferlin expression is screened in blood monocytes. All three tested patients showed complete absence of dysferlin expression, giving strong evidence of dysferlinopathy that was recently confirmed by mutation analysis. In conclusion, we would suggest the presented diagnostic strategy as a reliable and non-invasive method to be used as an alternative to muscle tissue protein analysis in routine diagnostics of dysferlinopathies, prior to the more complex and demanding search for causative DYSF mutations. This non-aggressive approach seems especially useful in situation in which multiplex Western blot (WB) analysis of different muscular dystrophy proteins on muscle sample is not available.
introduction
The term "dysferlinopathy" DYSF gene encodes dysferlin, a 237 kDa transmembrane protein belonging to a ferlin family of proteins, named after homology to C. elegans spermatogenesis factor Fer-1. The main characteristic of this protein family is the presence of multiple C2 domains (ranging from four to seven, latter being the number present in dysferlin), which are implicated in various biological processes [6] . Recent data suggest a role of dysferlin in the muscle fiber repair process [7] [8] [9] , myoblast differentiation [10] , T-tubulogenesis [11] , monocyte phagocytosis [12] and muscle regeneration [13] . Dysferlin is predominantly expressed in skeletal and heart muscle, where it localizes to the plasma membrane of muscle fibers [14, 15] . In addition, dysferlin is also found in blood monocytes, brain, lung and placenta [2, 3, [15] [16] [17] .
Although accurate and definitive diagnosis of dysferlinopathies relies on direct gene mutation analysis, screening of the whole gene for mutations is laborious, expensive, timeconsuming and an inappropriate approach for routine laboratories. Protein analysis, on the other hand, proved to be reliable for differential diagnostics of muscular dystrophies [1, 18] . Moreover, above mentioned dysferlin expression in blood monocytes enabled the development of a blood-based assay that analyses dysferlin expression from a peripheral blood sample [16] . This assay is a relatively simple and quick method of dysferlin analysis, resembling the usual protein analysis from muscle. However, it is a significantly less invasive and painless approach that overcomes the problems associated with handling and storage of muscle samples. Therefore it represents a valuable alternative to muscle tissue protein analysis, as well as an important and decisive step prior to the start of demanding gene mutational analysis.
Herein, we present the application of the specific diagnostic strategy [19] adapted to our population of 4,29 milion people, followed by linkage anaylsis and monocyte protein analysis of dysferlin that has permitted us to confirm the first diagnosis of dysferlinopathy in two families from Croatia.
materials and methods

Patients
A total of three patients from two unrelated families were included in the study (Figure 1) . In 
Methods
Following informed consent, peripheral blood samples were used for DNA extraction of patients and family members (presented in Figure 1 ) and monocyte isolation of the three patients. DNA was extracted using standard salting-outand procedure [20] , while monocyte isolation is described later in the text. and as previously described [16, 21] . Isolated monocytes were then lysed with a lysis buffer consisting of 20mM Tris-HCl (pH 7.5), 150mM
NaCl, 1mM Na 2 EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM sodium-pyrophosphate, 1mM
β-glycerolphosphate, 1mM Na 3 VO 4 , 1μg/ml leupeptin and 1mM PMSF.
Protein analysis. Protein concentration was determined using the Bradford protein assay.
Approximately 20 µg of proteins (from muscle homogenate and cell lysate, respectively)
were separated on a 4-7% gradient SDS-PAGE.
Immunoblotting was performed as previously described [22] , using anti-dysferlin primary 
results
Diagnosis suggested by clinical features was followed by linkage analysis and then by protein analysis on isolated monocytes from peripheral blood. This might indicate the existence of the same mutation on both alleles in each of the two studied families. These findings could be useful in future testings of new dysferlinopathy families from the same region of Croatia.
discussion
As linkage analysis was in accordance with dysferlinopathy, our next diagnostic step was to check dysferlin expression, as previously published studies showed the reliability of this approach in confirming LGMD2B diagnosis [18, 28] . In order to avoid the more invasive method of muscle biopsy we focused on a recently developed blood based assay, that analyses dysferlin expression in non-muscle tissue, i.e. a blood sample. Western blotting (WB) on monocytes was done according to the protocol described first by Ho et al. [16] and later improved by de Luna et al. [21] . This There are several publications containing data that suggest that dysferlin analysis from a blood sample is a major improvement in 
